Cargando…
Design, Synthesis, and Antisickling Investigation of a Thiazolidine Prodrug of TD-7 That Prolongs the Duration of Action of Antisickling Aromatic Aldehyde
The synthetic allosteric effector of hemoglobin, TD-7 has been investigated as a potential therapeutic agent for the treatment of sickle cell disease. The pharmacologic activity of TD-7 is due to formation of a Schiff-base interaction between its aldehyde group and the two N-terminal αVal1 amines of...
Autores principales: | Alhashimi, Rana T., Ahmed, Tarek A., Alghanem, Lamya, Pagare, Piyusha P., Huang, Boshi, Ghatge, Mohini S., Omar, Abdelsattar M., Abdulmalik, Osheiza, Zhang, Yan, Safo, Martin K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675597/ https://www.ncbi.nlm.nih.gov/pubmed/38004527 http://dx.doi.org/10.3390/pharmaceutics15112547 |
Ejemplares similares
-
VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions
por: Abdulmalik, Osheiza, et al.
Publicado: (2020) -
Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease
por: Alhashimi, Rana T., et al.
Publicado: (2022) -
Improving the Solubility and Oral Bioavailability of a Novel Aromatic Aldehyde Antisickling Agent (PP10) for the Treatment of Sickle Cell Disease
por: Ahmed, Tarek A., et al.
Publicado: (2021) -
Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin. Corrigendum
por: Abdulmalik, Osheiza, et al.
Publicado: (2011) -
Structural modification of azolylacryloyl derivatives yields a novel class of covalent modifiers of hemoglobin as potential antisickling agents
por: Omar, A. M., et al.
Publicado: (2019)